News | July 10, 2024
Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Subscribe To Our Newsletter & Stay Updated
